Abstract:

Objective: Rezum™ system is a safe minimal invasive treatment modality for benign prostate hyperplasia (BPH) treatment. The aim of this study was to evaluate the short-term results of Rezum™ therapy in our center. Materials and Methods: We retrospectively collected the data of 28 patients with symptomatic BPH who underwent Rezum™ therapy in our center. All patients’ pre-operative and post-operative; post-void residual volume (PVR), Qmax, international prostate symptom score (IPSS), quality of life (QoL) score, serum total prostate-specific antigen levels were obtained. The number of injections administered during the procedure, operation time, catheter removal time, complications and mean duration of follow-up was recorded. Results: Our study group consisted of 28 patients with a mean age of 65.1±8.9 years, median prostate volume 64 [interquartile range (IQR) 44.8-89.5] mL. The median procedure time was 12 (IQR 11-13.8) minutes, the median catheter removal time was 6.5 (IQR 5-8.8) days for our study group. None of the patients had experienced Clavien-Dindo 3 complications. Pre-operative median Qmax and PVR were 8 (IQR 6-9) mL/s and 110 (IQR 80-187.5) cc and post-operative Qmax and PVR were 12.5 (11-14.8) mL/s and 40 (IQR 18.8-70) cc, respectively. We observed a significant increase in IPSS and QoL score at post-operative 3rd month after the Rezum™ therapy. Conclusion: Rezum™ procedure is an effective and safe treatment for symptomatic BPH in the short term. Rezum™ system provides a significant increase in Qmax and significant decrease in PVR and IPSS. QoL scores after the 3rd month of the procedure is significantly lower compared to the pre-operative status.

Keywords: